Abstract
目前,原发性肝癌(HCC)患者的5年生存率尚不到10％.HCC易侵犯门静脉形成癌栓,几率高达30.0％～60.2％[1].门静脉癌栓(portal vein tumor thrombus,PVTT)形成被认为是影响HCC预后的独立因素[2].我科自2008年采用腔内植入125Ⅰ粒子条及支架联合经肝动脉化疗栓塞术(transcatheter arterial chemoembolization,TACE)治疗HCC合并门静脉主干癌栓取得了良好的疗效[3].但该疗法要求患者的门静脉二级分支血流必须通畅,部分晚期原发性肝癌患者往往出现广泛性PVTT,因门静脉二级分支血管闭塞,或癌栓超过肠系膜上静脉或脾静脉,无法放置内支架.故我们采用B超引导下经皮门静脉腔内125Ⅰ粒子条联合TACE治疗HCC合并PVTT. 关键词：癌,肝细胞;门静脉系统;125Ⅰ粒子;经动脉化疗栓塞术;癌栓
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
